The Tumor Microenvironment and Lymphatic Remodeling in Postpartum Breast Cancer
The Tumor Microenvironment and Lymphatic Remodeling in Postpartum Breast Cancer
批准号:
10651864
负责人:
Jasmine Alise McDonald
金额:
$55.98万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-07-01 至 2027-06-30
关键词:
AddressAgeAnimalsAnti-Inflammatory AgentsAspirinBehaviorBiological ProcessBiologyBlack raceBreast Cancer Risk FactorBreast Cancer TreatmentBreast FeedingCancer PrognosisCatalogsCd68CellsChildbirthClinicalClinical MarkersDataDiagnosisDiagnosticDiseaseElementsEnvironmentEvidence based treatmentGoalsImmunofluorescence ImmunologicImmunohistochemistryImmunomodulatorsImmunosuppressionIncidenceInflammationIntakeJointsLife StyleLinkLiverLymphangiogenesisLymphaticMacrophageMammary NeoplasmsMammary glandMeasurableMeasuresMediatingModelingMolecular ProfilingNeoplasm MetastasisNon-Steroidal Anti-Inflammatory AgentsNot Hispanic or LatinoNulliparityOutcomePD-1/PD-L1PathologicPathologic ProcessesPathologyPathway interactionsPatientsPhenotypePhysical activityPhysical shapePostpartum PeriodPredispositionPregnancyPrevention strategyPrognosisProteinsRecurrent Malignant NeoplasmRiskRisk FactorsRoleSamplingSemaphorinsTherapeuticTissuesTumor BiologyTumor Cell InvasionTumor-infiltrating immune cellsWomanagedanti-PD1 therapybehavioral phenotypingbreast cancer diagnosisbreast cancer family registrycancer recurrencecarcinogenesiscaregivingcohortdensitygenomic signaturehigh riskhuman dataimmune cell infiltrateimmunoregulationimprovedimproved outcomeinsightlymphatic vasculaturelymphatic vesselmalignant breast neoplasmmodifiable behaviormodifiable riskmortalitymortality riskmouse modelparouspermissivenesspodoplaninpost pregnancypostpartum breast cancerpre-clinicalpredictive markerprognosticpublic health prioritiesrisk stratificationtargeted treatmenttrendtumortumor growthtumor microenvironmenttumor progressionyoung woman
中文摘要
摘要/摘要:
从长远来看,怀孕会降低乳腺癌(BC)的风险,但与BC的增加有关,这种增加被称为
产后乳腺癌(PPBC)在分娩后至少十年。PPBC通常对这两种情况都更具侵略性
与非PPBC相比,晚期和更高的死亡风险。目前唯一可供告知的信息
降低PPBC的可能方法是基于母乳喂养,最近,非母乳喂养可能起到的作用
类固醇抗炎药(NSAIDs)。除了关于如何修改PPBC风险的稀少数据外,更少的是
与PPBC诊断后风险分层相关的信息,以改善常规基因组学结果
签名和临床标记物不适合被诊断为BC的年轻女性。我们的目标是解决这些主要问题
通过检查PPBC的肿瘤内环境来发现差距。研究表明淋巴管的扩张
产后重塑期间的血管系统、炎症和免疫抑制增加的特征
如果没有或提前停止母乳喂养,乳腺会恶化,从而使
环境对肿瘤的生长更为宽容。这种放任直接导致了
肿瘤的侵袭和转移与年轻女性BC死亡率的上升有关。肿瘤浸润性
免疫细胞通过它们的类型、功能以及与肿瘤和其他间质成分的相互作用,提供
代表肿瘤微环境(TME)的可测量的病理特征。前景看好的数据
提示信号素7A(SEMA7A)、CD68和泊多拉宁(PDPN)的丰富与不良相关
BC预后,机制尚不清楚。因此,我们将描述巨噬细胞介导的TME的特征
用SEMA7A、CD68、PDPN和PD-L1/PD-1检测淋巴管生成和免疫抑制
通过多光谱定量免疫荧光在1例年轻女性BC病例中的表达
152例PBC患者(出生后5年确诊)与272例非PPBC患者(诊断为≥10年)相匹配
从分娩开始)确诊时的年龄。我们将通过测量功能特定的TME表型
蛋白质丰度与肿瘤和淋巴管的空间邻近程度之间的独立和联合关系
脉管系统。我们将单独和共同检查每种表型,以开发TME多表型
得分。我们的目标是研究功能特异的TME表型和TME表型之间的独立关联
建立的TME多表型评分与(1)PPBC状态和(2)总生存期有关。我们还(3)检查
诊断前生活方式行为(如母乳喂养、非甾体抗炎药摄入量、体力活动)之间的关系
以及TME表型和评分。没有基因组签名或临床标记来告知治疗学
也不是年轻女性BC的预后。因此,对于年轻女性的BC总体和PPBC来说,战略是
需要定义预测性生物标志物,并提供对可修改的功能生物学的洞察
行为。据我们所知,这是第一次从密度和空间上考察TME特征的研究
为年轻女性的BC和第一个临时性检查生活方式行为和乳房TME的病理学。
英文摘要
SUMMARY/ABSTRACT:
Pregnancy reduces breast cancer (BC) risk in the long-run but is associated with increased BC known as
postpartum breast cancer (PPBC) for at least a decade after delivery. PPBC is often more aggressive with both
late stage and higher risk of death compared to non-PPBC. Currently the only available information to inform
women of possible ways to reduce PPBC is based on breastfeeding and more recently, a possible role for non-
steroidal anti-inflammatories (NSAIDs). In addition to sparse data on how to modify PPBC risk, there is even less
information related to risk stratification after PPBC diagnosis to improve outcomes with routine genomic
signatures and clinical markers not suited for young women diagnosed with BC. We aim to address these major
gaps by examining the intratumoral PPBC environment. Studies suggest that the expansion of the lymphatic
vasculature, inflammation, and increased features of immune suppression during postpartum remodeling of the
mammary gland is exacerbated in the absence- or early-cessation- of breastfeeding which makes the
environment more permissive to tumor growth. This permissiveness contributes directly to the increased risk of
tumor invasion and metastasis linked to the rising rates of BC mortality in young women. The tumor infiltrating
immune cells, through their type, function, and interactions with the tumor and other stromal elements, provide
a measurable pathological signature representative of the tumor microenvironment (TME). Promising data
suggests that enrichment for Semaphorin 7A (SEMA7A), CD68, and Podoplanin (PDPN) is associated with poor
BC prognosis, with mechanisms unclear. Therefore, we will profile the TME for features of macrophage mediated
lymphangiogenesis and immune suppression, as measured by SEMA7A, CD68, PDPN, and PD-L1/PD-1
expression via multispectral quantitative immunofluorescence, in a young women’s BC case-cohort of
152 PPBC cases (diagnosed <5 years from childbirth) matched to 272 non-PPBC cases (diagnosed ≥10 years
from childbirth) on age at diagnosis. We will measure functional-specific TME phenotypes by measuring the
independent and joint associations between protein abundance and spatial proximity to tumor and the lymphatic
vasculature. We will examine each phenotype independently and together to develop TME poly-phenotype
scores. We aim to examine the independent association between the functional-specific TME phenotypes and
the developed TME poly-phenotype score with (1) PPBC status and (2) overall survival. We also (3) examine
the association between prediagnostic lifestyle behaviors (i.e., breastfeeding, NSAID intake, physical activity)
and TME phenotypes and scores. There are no genomic signatures or clinical markers that inform therapeutics
nor prognosis for young women’s BC. Thus, for young women’s BC overall and PPBC specifically, strategies are
needed that define predictive biomarkers and provides insight into the functional biology of modifiable
behaviors. To our knowledge, this is the first study to examine TME features through density and spatial
pathology for young women’s BC and the first to temporally examine lifestyle behaviors and the breast TME.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Training in Health Equity, Highlighting Environmental Inequities, & Growing neighborHood Teachers and Students (YES in THE HEIGHTS)
-
批准号:10516343
-
项目类别:
-
资助金额:$32.18万
-
财政年份:2022
-
负责人:Jasmine Alise McDonald
-
依托单位:
Training in Health Equity, Highlighting Environmental Inequities, & Growing neighborHood Teachers and Students (YES in THE HEIGHTS)
-
批准号:10680502
-
项目类别:
-
资助金额:$34.28万
-
财政年份:2022
-
负责人:Jasmine Alise McDonald
-
依托单位:
The Tumor Microenvironment and Lymphatic Remodeling in Postpartum Breast Cancer
-
批准号:10522393
-
项目类别:
-
资助金额:$56.2万
-
财政年份:2022
-
负责人:Jasmine Alise McDonald
-
依托单位:
The Tumor Microenvironment and Lymphatic Remodeling in Postpartum Breast Cancer
-
批准号:10818934
-
项目类别:
-
资助金额:$10.23万
-
财政年份:2022
-
负责人:Jasmine Alise McDonald
-
依托单位:
Childhood Infection and Pubertal Timing
-
批准号:9304152
-
项目类别:
-
资助金额:$13.94万
-
财政年份:2015
-
负责人:Jasmine Alise McDonald
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: